The downregulation of TRAF3IP2-AS1 resulted in reduced PTEN expression, facilitating the progression of NONO-TFE3 tRCC by inducing the m6A modification of PARP1 mRNA. The gene discussed is PARP1; the disease is renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.